title: Recent advances in drug eluting stents.
abstract: One of the most common medical interventions to reopen an occluded vessel is the implantation of a coronary stent. While this method of treatment is effective initially, restenosis, or the re-narrowing of the artery frequently occurs largely due to neointimal hyperplasia of smooth muscle cells. Drug eluting stents were developed in order to provide local, site-specific, controlled release of drugs that can inhibit neointima formation. By implementing a controlled release delivery system it may be possible to control the time release of the pharmacological factors and thus be able to bypass some of the critical events associated with stent hyperplasia and prevent the need for subsequent intervention. However, since the advent of first-generation drug eluting stents, long-term adverse effects have raised concerns regarding their safety. These limitations in safety and efficacy have triggered considerable research in developing biodegradable stents and more potent drug delivery systems. In this review, we shed light on the current state-of-the-art in drug eluting stents, problems related to them and highlight some of the ongoing research in this area.
authors.affiliation: Department of Chemical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
authors.forename: Amey S
authors.initials: AS
authors.lastname: Puranik
authors.forename: Eileen R
authors.initials: ER
authors.lastname: Dawson
authors.forename: Nicholas A
authors.initials: NA
authors.lastname: Peppas
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000601:surgery*; D054059:Coronary Occlusion / Q000601:surgery; D023903:Coronary Restenosis / Q000517:prevention & control; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D054855:Drug-Eluting Stents / Q000009:adverse effects; D006801:Humans; D058426:Neointima / Q000517:prevention & control; D015607:Stents / Q000009:adverse effects
chemical_list: D003692:Delayed-Action Preparations